Sarah Abou Alaiwi

Sarah Abou Alaiwi

Auto-generated profile, based on publicly available information

Sarah Abou Alaiwi

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PCPaloma Cejas
Paloma Cejas
YXYingtian Xie
Yingtian Xie
AFAlba Font-Tello
Alba Font-Tello
KLKlothilda Lim
Klothilda Lim
SSSudeepa Syamala
Sudeepa Syamala
HLHenry W. Long
Henry W. Long
Neuroendocrine carcinomas (NEC) are tumors expressing markers of neuronal differentiation that can arise at different anatomic sites but have strong histological and clinical similarities. Here we report the chromatin landscapes of a range of human NECs and show convergence to the activation of a common epigenetic program. With a particular focus on treatment emergent neuroendocrine prostate cancer (NEPC), we analyze cell lines, patient-derived xenograft (PDX) models and human clinical samples to show the existence of two distinct NEPC subtypes based on the expression of the neuronal transcription factors ASCL1 and NEUROD1. While in cell lines and PDX models these subtypes are mutually exclusive, single-cell analysis of human clinical samples exhibits a more complex tumor structure with subtypes coexisting as separate sub-populations within the same tumor. These tumor sub-populations differ genetically and epigenetically contributing to intra- and inter-tumoral heterogeneity in human metastases. Overall, our results provide a deeper understanding of the shared clinicopathological characteristics shown by NECs. Furthermore, the intratumoral heterogeneity of human NEPCs suggests the requirement of simultaneous targeting of coexisting tumor populations as a therapeutic strategy.

30 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSylvan C. Baca
Sylvan C. Baca
DTDavid Y. Takeda
David Y. Takeda
JSJi-Heui Seo
Ji-Heui Seo
JHJustin Hwang
Justin Hwang
SKSheng Yu Ku
Sheng Yu Ku
MFMatthew Freedman
Matthew Freedman
Lineage plasticity, the ability of a cell to alter its identity, is an increasingly common mechanism of adaptive resistance to targeted therapy in cancer. An archetypal example is the development of neuroendocrine prostate cancer (NEPC) after treatment of prostate adenocarcinoma (PRAD) with inhibitors of androgen signaling. NEPC is an aggressive variant of prostate cancer that aberrantly expresses genes characteristic of neuroendocrine (NE) tissues and no longer depends on androgens. Here, we investigate the epigenomic basis of this resistance mechanism by profiling histone modifications in NEPC and PRAD patient-derived xenografts (PDXs) using chromatin immunoprecipitation and sequencing (ChIP-seq). We identify a vast network of cis-regulatory elements (N~15,000) that are recurrently activated in NEPC. The FOXA1 transcription factor (TF), which pioneers androgen receptor (AR) chromatin binding in the prostate epithelium, is reprogrammed to NE-specific regulatory elements in NEPC. Despite loss of dependence upon AR, NEPC maintains FOXA1 expression and requires FOXA1 for proliferation and expression of NE lineage-defining genes. Ectopic expression of the NE lineage TFs ASCL1 and NKX2-1 in PRAD cells reprograms FOXA1 to bind to NE regulatory elements and induces enhancer activity as evidenced by histone modifications at these sites. Our data establish the importance of FOXA1 in NEPC and provide a principled approach to identifying cancer dependencies through epigenomic profiling.

5 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZBZiad Bakouny
Ziad Bakouny
DBDavid A. Braun
David A. Braun
SSSachet A. Shukla
Sachet A. Shukla
WPWenting Pan
Wenting Pan
XGXin Gao
Xin Gao
TCToni K. Choueiri
Toni K. Choueiri
Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC) are highly aggressive tumors with limited molecular and clinical characterization. Emerging evidence suggests immune checkpoint inhibitors (ICI) are particularly effective for these tumors, although the biological basis for this property is largely unknown. Here, we evaluate multiple clinical trial and real-world cohorts of S/R RCC to characterize their molecular features, clinical outcomes, and immunologic characteristics. We find that S/R RCC tumors harbor distinctive molecular features that may account for their aggressive behavior, including BAP1 mutations, CDKN2A deletions, and increased expression of MYC transcriptional programs. We show that these tumors are highly responsive to ICI and that they exhibit an immune-inflamed phenotype characterized by immune activation, increased cytotoxic immune infiltration, upregulation of antigen presentation machinery genes, and PD-L1 expression. Our findings build on prior work and shed light on the molecular drivers of aggressivity and responsiveness to ICI of S/R RCC.

16 December 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SGStefan Groha
Stefan Groha
SASarah Abou Alaiwi
Sarah Abou Alaiwi
WXWenxin Xu
Wenxin Xu
VNVivek Naranbhai
Vivek Naranbhai
Amin NassarAmin Nassar
Amin Nassar
AGAlexander Gusev
Alexander Gusev

23 December 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
EAElio Adib
Elio Adib
TZTalal El Zarif
Talal El Zarif
Amin NassarAmin Nassar
Amin Nassar
EAElie W. Akl
Elie W. Akl
SASarah Abou Alaiwi
Sarah Abou Alaiwi
GSGuru P. Sonpavde
Guru P. Sonpavde
Background and aims: CDH1 germline variants have been linked to heritability in diffuse gastric (DGC) and lobular breast cancer (LBC). Studies have not yet assessed whether CDH1 is a cancer-susceptibility gene in other cancers. Herein, we mapped the landscape of pathogenic and likely pathogenic (P/LP) germline variants in CDH1 across various cancers and ethnicities. Methods: We evaluated CDH1 germline P/LP variants in 212,944 patients at one CLIA-certified laboratory (Invitae) and described their frequency in 7 cancer types. We screened for CDH1 variant enrichment in each cancer relative to a cancer-free population from The Genome Aggregation Database version 3 (gnomADv3). Results: CDH1 P/LP variants were identified in 141 patients, most commonly in patients with DGC (27/408, 6.6%) followed by colorectal signet-ring cell cancer (CSRCC; 3/79, 3.8%), gastric cancer (56/2756, 2%), and LBC (22/6809, 0.3%). CDH1 P/LP variants were enriched in specific ethnic populations with breast cancer, gastric cancer, CRC, LBC, DGC, and CSRCC compared to matched ethnicities from gnomADv3. Conclusion: We report for the first time the prevalence of P/LP CDH1 variants across several cancers and show significant enrichment in CDH1 P/LP variants for patients with CSRCC, DGC, and LBC across various ethnicities. Future prospective studies are warranted to validate these findings.

29 April 2022 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
NVNuzzo Pier Vitale
Nuzzo Pier Vitale
EAElio Adib
Elio Adib
NWNicole Weise
Nicole Weise
CCCatherine Curran
Catherine Curran
TSTyler Stewart
Tyler Stewart
GSGuru P. Sonpavde
Guru P. Sonpavde